Abstract
Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Current Drug Safety
Title:Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis
Volume: 10 Issue: 2
Author(s): Raoudha Slim, Neila Fathallah, Amina Aounallah, Mehdi Ksiaa, Badreddine Sriha, Rafiaa Nouira and Chaker Ben Salem
Affiliation:
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Abstract: Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Export Options
About this article
Cite this article as:
Slim Raoudha, Fathallah Neila, Aounallah Amina, Ksiaa Mehdi, Sriha Badreddine, Nouira Rafiaa and Salem Ben Chaker, Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140827122735
DOI https://dx.doi.org/10.2174/1574886309666140827122735 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews The Antidepressant-like Effects of Estrogen-mediated Ghrelin
Current Neuropharmacology L-Type Voltage-Dependent Calcium Channels As Therapeutic Targets for Neurodegenerative Diseases
Current Medicinal Chemistry Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Efficacy and Activity Prediction by Molecular Topology of New Drugs Against the Tetranychus urticae Plague
Combinatorial Chemistry & High Throughput Screening Cancer Electrogene Therapy with Interleukin-12
Current Gene Therapy Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Thioredoxin Reductase and its Inhibitors
Current Protein & Peptide Science HIV-Induced Abnormalities in Myelopoiesis and their Recovery Following Antiretroviral Therapy
Current HIV Research Osmoadaptation of Mammalian Cells - An Orchestrated Network of Protective Genes
Current Genomics Anti-TNF and Crohns Disease: When Should we Start?
Current Drug Targets Dendrimers as Biopharmaceuticals: Synthesis and Properties
Current Topics in Medicinal Chemistry Biosynthesis and Genetic Engineering of Lipopeptide Antibiotics Related to Daptomycin
Current Topics in Medicinal Chemistry HIV-1-Discordant Couples in Sub-Saharan Africa: Explanations and Implications for High Rates of Discordancy
Current HIV Research Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
CNS & Neurological Disorders - Drug Targets Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Potential Anti-inflammatory Effects of Hesperidin from the Genus Citrus
Current Medicinal Chemistry Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine